AstraZeneca Plans $1.5B Manufacturing Facility For Antibody Drug Conjugates In Singapore, AstraZeneca Expects To Begin Design And Construction By The End Of 2024, With Targeted Operational Readiness From 2029
AstraZeneca Plans $1.5B Manufacturing Facility For Antibody Drug Conjugates In Singapore, AstraZeneca Expects To Begin Design And Construction By The End Of 2024, With Targeted Operational Readiness From 2029
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.